Skin dendritic cells (DC) are believed to play an important role in both the initiation and regulation of skin alloimmunity. We have developed a technique for the isolation and characterization of distinct skin DC subsets and have demonstrated the dynamics and the associated immune response profiles in vascularized composite allotransplantation (VCA). Resident skin DC can migrate out of allogeneic skin into the recipient's skin and draining lymph nodes, and may exert regulatory functions after VCA. Thus, isolating migratory skin DC from limb transplants and examining their capacity to effect T cell immune responses is part of our ongoing effort. In the present study, we assessed the function of skin-resident and skin-migrated DC subsets on regulating the T-cell immune response and characterized their changes in VCA under topical FK506 immunosuppression.
PURPOSE:
Skin dendritic cells (DC) are believed to play an important role in both the initiation and regulation of skin alloimmunity. We have developed a technique for the isolation and characterization of distinct skin DC subsets and have demonstrated the dynamics and the associated immune response profiles in vascularized composite allotransplantation (VCA). Resident skin DC can migrate out of allogeneic skin into the recipient's skin and draining lymph nodes, and may exert regulatory functions after VCA. Thus, isolating migratory skin DC from limb transplants and examining their capacity to effect T cell immune responses is part of our ongoing effort. In the present study, we assessed the function of skin-resident and skin-migrated DC subsets on regulating the T-cell immune response and characterized their changes in VCA under topical FK506 immunosuppression.
METHODS: 1)
To evaluate the impact of topical immunosuppressive treatment on the skin DC in VCA, LEW rats received hindlimb transplants from BN rats and were treated with topical FK506 (0.5mg 0.1% FK506 ointment, applied once daily). Skin-resident DC from transplanted limbs were isolated at day 8 post-transplantation using our established methods and quantification of skin DC subsets were analyzed by flow cytometry.Skin DC isolated from Naïve or 7-day topical FK506 treated untransplanted LEW rats were used as comparison groups. 2) To determinethe function of skin migratory DC on the T cell immune response, DC from each group were isolated in vitro and were characterized by subset and functional specialization by mixed lymphocyte reaction(MLR) and flow cytometric analysis.
RESULTS: 1) After topical FK506 treatment, skin-resident dermal DC (DDC) declined with an elevation trend in Langerhans cells (LC). 2) Migrated LC and mature skin DC were lower, while DDC were slightly higher in FK506-treated skin explant cultures compared to naïve skin. 3) In MLR, skin-migrated DC inhibited effector T cell (Teff) proliferation and exhibited synergistic effects with regulatory T cells (Treg). 4) The addition of skin-migrated DC promoted Foxp3 expression in CD4+ T cells. In contrast, the addition of skin-resident DC decreased Foxp3 and promoted IL-17 expression.
CONCLUSIONS:
In vivo alterations of skin-resident DC subsets and ex vivo emigration and maturation of skin DC are affected by a short-term topical immunosuppression in VCA.There is differential contribution of skin-migrated and skin-resident DC to the effector T cell response in vitro. The determination of skin-migrated DC in regulating T-cell immune responses will provide a target for immunomodulation. transplantation is a clinical reality but limited by toxicities of chronic immunosuppression and rejection. Current clinical tolerance protocols rely on recipient conditioning and donor cell mobilization that limits use to living donor transplants. We sought to design a clinically relevant protocol applicable to cadaveric organs. We have previously demonstrated stem cell engraftment using AMD3100 (Plerixafor) as a single dose agent for stem cell mobilization in a haploidentical canine model. We wanted to increase clinical relevance by testing our existing non-myeloablative stem cell canine VCA transplant model to full DLA-mismatched, unrelated canine donor-recipient pairs.
METHODS: 8 DLA haploidentical, related canine recipients (Group I) and 4 full DLA-mismatched, unrelated canine recipients (Group II) received conditioning with 350-450cGy TBI, AMD3100-mobilized donor stem cells + Bone Marrow (BM) infusion and simultaneous VCA transplantation with a short course of immunosuppression (MMF: 56 days/CSP: 70 days. Sirolimus 28 days added as third agent for Group II). CD34+ hematopoietic progenitor cells were quantified via flow cytometry. Peripheral blood chimerism was evaluated by PCR techniques weekly. VCA graft survival was followed clinically and histologically.
RESULTS:
All 12 canines tolerated the conditioning regimen. Stem cell engraftment and donor chimerism was seen in all dogs. Mean COBE apheresis count was 3.98x10^8 cells/kg and mean BM aspirate count was 1.56x10^8 cells/ kg across both groups (12 dogs). Outcomes were varied. In Group I there was evidence of an acute rejection episode (self-limited) in 1 dog. Evidence of GVHD (skin, liver) was seen in 3 dogs and pulmonary hemorrhage noted in 3 dogs. In Group II there was no evidence of acute rejection, however GVHD (skin, liver) was seen in 2 dogs. 2 dogs were lost post-transplant to complications of intussusception while still seemingly tolerant to the VCA.
CONCLUSION:
This study demonstrates proof of principle for AMD3100 as a single-dose stem cell mobilizing agent for a clinically relevant tolerance protocol in both related haplotype and in mismatched, unrelated donorrecipient pairs. Use of AMD3100 led to stem cell engraftment in all animals transplanted with evidence of acute rejection in the VCA in only one canine. AMD3100 use limited by thrombocytopenia in our previous studies continue to appear be resolved with the addition of BM Aspirate in this model. Continued experiments should allow for longerterm follow up in future canine recipients that should optimistically not experience bowel complications or GVHD.
